Lidocaina Grindeks (Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels on neuronal membranes, stabilizing them in an inactive state. This prevents the rapid influx of sodium ions required for depolarization, thereby inhibiting the initiation and propagation of nerve impulses and producing a reversible loss of sensation in the targeted area.

The dose of Lidocaina Grindeks is determined by the prescribing clinician based on the specific procedure, route of administration, patient weight, and overall health status. Healthcare providers calculate the appropriate amount to stay within recommended safety limits.

Safety data for lidocaine during pregnancy and lactation are limited. Use is generally reserved for situations where the benefit to the mother outweighs potential risks to the fetus or infant, and it should be administered only under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lidocaine has a relatively rapid onset and moderate duration of action compared with agents such as bupivacaine, which has a slower onset but longer duration. Lidocaine’s safety profile is well‑characterized, making it a common first‑line choice for many short‑ to medium‑duration procedures.

Store the product below 25 °C in its original container, protecting it from direct light and moisture. Avoid freezing. Before use, inspect the solution for particulate matter or discoloration and discard if any abnormalities are observed.

Lidocaina Grindeks is administered by injection via epidural, intravenous, or subcutaneous routes, depending on the clinical indication. Administration must be performed by trained healthcare professionals using aseptic technique and appropriate dosing calculations.

Serious adverse events include cardiac arrhythmias, seizures, methemoglobinemia, and severe allergic reactions such as anaphylaxis. Prompt recognition and management of these events are essential, and patients should be monitored closely during and after administration.

Lidocaina Grindeks is contraindicated in individuals with a known hypersensitivity to lidocaine or other amide‑type local anesthetics, patients with severe heart block or uncorrected ventricular arrhythmias, and those with certain metabolic disorders that increase susceptibility to toxicity.